Gilead Sciences HIV Franchise Can Perform Better Than Expected - Bidness ETC
Bidness ETCGilead Sciences HIV Franchise Can Perform Better Than ExpectedBidness ETCThe research firm also expects patients on Gilead's Atripla (efavirenz, emtricitabine and TDF) to switch to Genvoya with time, since the former is no longer recommended as a first-line HIV treatment by the US Department of Health & Human Services (DHHS .
Efavirenz-based treatment is safe and effective for young children with HIV exposed to nevirapine for PMTCT - aidsmap
Efavirenz-based treatment is safe and effective for young children with HIV exposed to nevirapine for PMTCTaidsmapEfavirenz-based treatment is a safe and effective treatment option for children living with HIV previously exposed to nevirapine for the prevention of mother-to-child transmission (PMTCT) who achieved viral suppression with a regimen based on .
South Africa: New, Better HIV Drugs Can Save Billions of Rand - AllAfrica.com
Switch to Efavirenz-based ART Effective Option in Kids - Medscape
MedscapeSwitch to Efavirenz-based ART Effective Option in KidsMedscapeHIV-infected children previously exposed to nevirapine to prevent maternal HIV transmission who are switched to efavirenz-based therapy do not have significantly higher rates of viral rebound or viral failure compared with those who continue receiving .
Effectiveness of efavirenz-based antiretroviral therapy for HIV-infected children - Science Daily
Effectiveness of efavirenz-based antiretroviral therapy for HIV-infected childrenScience DailyThe researchers found that switching to efavirenz-based therapy compared with continuing ritonavir-boosted lopinavir-based therapy did not result in significantly higher rates of viral rebound (i.